According to the rapid increase of the modern research and studies related to the problem of erectile dysfunction, the condition can be defined as widely spreading. Over 20% of male population is affected by one of the most common sexual disorders. The physiological processes, which trigger erection, have been thoroughly studied, with phosphodiesterase 5 inhibitors giving a significant advancement. Currently, new agents, such as melanocortin and dopaminergic receptor agonists, are under investigation, as they target central erectogenic pathway and can considerably advance the male ability to achieve and hold an erection. New formulas, techniques, and methods appear on the market becoming revolutionary approaches to the erectile dysfunction treatment.
Erectile dysfunction is a widely spread condition among men, which features considerable public health implications. The issue can be defined as an inability to achieve and hold an erection for sufficient time. A range of comorbid conditions triggers impotence occurrence, specifically obesity, hypertension, type II diabetes, cardiovascular disease and others. However, the modern pharmaceutical market is filled with ED treatments that can promote the necessary assistance and balance male sexual functioning rather fast. PDE 5 inhibitors were the first remedies offered on the market, though, currently, the number of medications is growing. Non-PDE 5 inhibitor oral agents, such as melanocortin receptor agonists, dopaminergic agents, soluble guanylate cyclase stimulators, Rho-kinase inhibitors and other treatments can considerably improve the condition.
In addition, patients can use one of the most innovative techniques and methods of ED treatment, including:
The effectiveness of PDE 5 inhibitors has contributed to their popularity, but over the past decade, when the deeper insight into the physiological and molecular pathway has been given, new treatments and techniques have appeared, improving ED fast and effectively.